Biologics Market Achieves USD 412 billion in 2024, Braces for 8.25% CAGR Elevate Until 2030

Comments · 91 Views

Biologics Market Achieves USD 412 billion in 2024, Braces for 8.25% CAGR Elevate Until 2030

In-Depth Analysis of the Global Biologics Market: 2024-2030 Forecasts

According to the latest findings by MarkNtel Advisors, The Global Biologics Market size was valued at USD 412 billion in 2024 and is estimated to grow at a CAGR of around 8.25% during the forecast period, i.e., 2024-30. The report provides an in-depth analysis of crucial aspects such as market trends, size, forecasts, growth factors, challenges, and competitor assessments. Conducting a thorough examination of the Biologics Market, the report offers insights into recent developments and presents an overview of the market landscape.

Biologics Market Segmentation Analysis:

Our research report meticulously explores the Biologics Market, breaking it down into these key segments: By Therapeutic Application (Oncology, Infectious Disease, Autoimmune Disease, Diabetes, Cardiovascular Diseases, Others (Inflammatory Bowel Diseases, Respiratory Disorders, Ophthalmic Disorders, etc.)), By Drug Class (Recombinant Proteins, [Hormones, Cytokines], Monoclonal Antibodies, Blood & Blood Components, Cellular & Gene Therapy, Vaccines, Others), By Source (Microbes, Humans, Others (Rodents, Plants, etc.)), Others. Each segment, along with its subdivisions, undergoes a detailed breakdown to offer a comprehensive understanding of the market dynamics.

Request Free Sample of the Report - https://www.marknteladvisors.com/query/request-sample/global-biologics-market.html

Geographical Coverage:

Our research report on the Biologics Market offers comprehensive coverage across different regions, including North America, South America, Europe, The Middle East & Africa, Asia-Pacific. It provides detailed information on growth potential in each country and region, offering valuable insights for market stakeholders to strategically plan future operations and investments.

Global Biologics Market Driver:

Increasing Inclination Towards Gene Therapy & Cellular Therapy to Boost the Market Growth – Due to their ability to repair or substitute damaged tissues, gene and cellular treatments have experienced considerable growth in adoption over the historical years. Moreover, the rising investments in research & development of cell and gene therapies have been further bolstering their adoption, owing to the improved efficacy of new drugs. Additionally, there has been increased funding and investments for R&D purposes of cell and gene therapies by companies like Ori Biotech, AstraZeneca Plc, GlaxoSmithKline Biologicals, etc., for the launch of innovative products.

Thus, with enhanced investment, the process of pre-commercialization and market launch has been accelerated, which has been contributing to the market growth. Also, over the historical years, the approvals of these medicines have been accelerated by government organizations like the United States Food and Drug Administration (FDA), the European Medicines Agency (EMA), etc. Consequently, as approvals for cell and gene therapies would accelerate in the coming years, it would create an opportunity for their enhanced adoption in the coming years as well.

View Full Report [Including Description + TOC] - https://www.marknteladvisors.com/research-library/global-biologics-market.html

Competitive Landscape of Biologics Market

The Biologics market witnesses’ fierce competition driven by the participation of both foreign and domestic companies. Considerable investments in Research and Development (R&D) have led to multiple innovations in the market. Companies with a global reach exert significant influence over the Biologics market, and it is anticipated that several international players will expand their global presence in the coming years. To maintain competitiveness amidst rivals, vendors must prioritize the development of new technologies and strive to stay ahead of imminent breakthroughs. The report underscores key players in the market, namely:

  • Bristol-Myers Squibb
  • Pfizer
  • Sanofi
  • Janssen Biotech, Inc.
  • Bayer AG
  • Merck & Co.
  • Amgen Inc.
  • Abbott GmbH
  • Novartis
  • AstraZeneca Plc
  • GlaxoSmithKline Biologicals
  • Moderna, Inc.
  • Ferring Pharmaceuticals Inc.
  • Aimmune Therapeutics, Inc.
  • Hoffman La Roche
  • Others

Sent Customized Report Inquiry - https://www.marknteladvisors.com/query/request-customization/global-biologics-market.html

Common Queries:

  1. What is the current trajectory of cost and profit estimations in the Biologics Industry?
  2. How do factors like supply and consumption shape the landscape of the industry?
  3. In what ways do import and export considerations impact the dynamics of the Biologics Industry?
  4. Which technological advancements are anticipated to shape the future of the Biologics Market?
  5. Who are the noteworthy players highlighted in the Biologics Market research report?
  6. What are the anticipated USD valuations and the CAGR for the forecasted years?

About Us

MarkNtel Advisors is a leading consulting, data analytics, and market research firm that provides an extensive range of strategic reports on diverse industry verticals. We being a qualitative & quantitative research company, strive to deliver data to a substantial & varied client base, including multinational corporations, financial institutions, governments, and individuals, among others.

We have our existence across the market for many years and have conducted multi-industry research across 80+ countries, spreading our reach across numerous regions like America, Asia-Pacific, Europe, the Middle East & Africa, etc., and many countries across the regional scale, namely, the US, India, the Netherlands, Saudi Arabia, the UAE, Brazil, and several others.

Contact Information:

  • Address: Office No.109, H-159, Sector 63, Noida, Uttar Pradesh - 201301, India
  • Call (India): +91 120 4278433
  • Call (USA): +1 628 895 8081
  • Email: [email protected]
Comments